Salesforce's Benioff invests in smart pregnancy wearable startup

Courtesy of Bloomlife
Bloomlife, a digital women’s health company, has closed on a $4 million seed funding round, bringing Bloomlife’s total funding to $6 million. Bloomlife will use the new funding toward commercialization efforts for a smart pregnancy wearable called Belli that measures contractions and displays them visually on a smartphone.

The round was led by Marc Benioff and Efficient Capacity, LanzaTech Ventures, MeusInvest, Hanmi IT, The Chernin Group, Kapor Capital and Act One Ventures.

Marc Benioff, founder of Salesforce, is no stranger to women’s issues in the tech world. He’s famously advocated for women in the tech workplace and seems to have set his eyes on helping women’s health.

Bloomlife has developed a sensor that can measure specific health parameters for a mother and child from conception through birth. Bloomlife hopes this tech--which earned honors at the Extreme Tech Challenge on Sir Richard Branson’s Necker Island--can help boost its mission to use crowdsourced data to enhance prenatal care through the understanding of pregnancy and its complications.

"Our company's mission resonated with the [Extreme Tech Challenge] judges," said Eric Dy, CEO and co-founder, in the announcement. "They understood how our technology could help this underserved market."


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.
Courtesy of Bloomlife

Bloomlife has ongoing partnerships with the University of California, San Francisco’s Preterm Birth Initiative and research teams at Stanford.

Belli can help expectant mothers have more peace of mind during the third trimester. Until it is launched, the wearable is only available through an Early Access Program on the Bloomlife website.

"Every pregnancy is unique and expectant moms are looking for validation of what they are feeling,” Dy explained in the announcement. “Bloomlife provides an objective second opinion."

- here's the announcement

Related Articles: 
Top VCs nurture consumer pregnancy startups, Glow and BellaBeat
Fitbit lends wearable tech to Dana-Farber for breast cancer study
Women's health biotech Forendo raises $15M from some pharma giants
FDA approved high-risk women's health devices without proper data: Study

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.